What Berifen Treats: Main Uses and Benefits

Berifen is used to provide symptomatic relief by addressing symptoms related to physical discomfort and inflammatory or irritative states. This type of medicine may assist in easing swelling and pain. Berifen is considered relevant in conditions involving episodic or fluctuating manifestations, commonly used to help with muscle aches, joint pain, and symptoms associated with acute or episodic changes, including menstrual cramps.

The medication is applied across domains where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom burden during symptomatic phases. By easing symptoms related to pain and swelling in joints, Berifen may also assist with maintaining functional stability and supporting better movement.

“The main benefit is considered the supportive relief it offers when daily comfort is interrupted by pain or stiffness.”

---

Quick Fact: Supportive Relief for Symptoms Related to Inflammation and Stiffness

---

This supportive action may help patients cope more steadily with symptom fluctuations, contributing to comfort during difficult episodes.

Who can and cannot use Berifen?

Eligibility for Berifen (Diclofenac) is strictly defined by regulatory authorities, focusing on absolute contraindications and population-specific restrictions.

---

Absolute Contraindications

Use is strictly contraindicated and must be avoided in populations with:

• Known hypersensitivity to diclofenac, aspirin, or any NSAID.
• Active gastrointestinal ulceration, bleeding, or perforation.
• Severe organ dysfunction, including severe hepatic failure, advanced renal disease, or established severe heart failure (NYHA Class II-IV).
• The last trimester of pregnancy (after 30 weeks gestation) and during the peri-operative period of Coronary Artery Bypass Graft (CABG) surgery.

---

Age and Restricted Use

Adults without contraindications are the primary approved population. Use is generally not approved for oral forms in the general population under 18 years old in some regions, and it is contraindicated for children under 14 for topical gel formulations. Elderly patients must use the medicine with particular caution and at the lowest effective dosage. For women between 20 and 30 weeks of pregnancy, use is restricted to the lowest dose for the shortest duration. Caution is also required for patients with a history of GI issues or significant cardiovascular risk factors.

Interactions with other medicines and products

The interaction profile of Berifen (Diclofenac) is officially structured by government regulatory documents to identify combinations that require restriction or careful monitoring.

---

Interaction-Related Restrictions

Berifen is contraindicated for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. It is also prohibited in patients who have experienced allergic-type reactions (such as aspirin-sensitive asthma) after taking Aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Concurrent use with Alcohol is avoided due to the documented increase in gastrointestinal bleeding risk.

Clinically Significant Interactions

Co-administration with Anticoagulants (e.g., Warfarin) and Antiplatelet Drugs significantly increases the documented risk of bleeding. The use of Berifen with ACE Inhibitors, ARBs, and Diuretics may diminish the blood pressure-lowering or natriuretic effect of these medicines. This interaction is noted to heighten the risk of renal function deterioration in elderly or renally impaired patients.

Exposure-Modifying Interactions

Diclofenac co-administration can increase the serum concentration and prolong the half-life of co-administered medicines, including Lithium, Digoxin, and Methotrexate. The use of Voriconazole (a known CYP inhibitor) is documented to increase the systemic exposure of Diclofenac itself. Furthermore, specific oral formulations must be administered on an empty stomach as food reduces their overall effectiveness.

The action of the drug is fundamentally based on the competitive inhibition of Cyclooxygenase (COX) enzymes, specifically targeting both COX-1 and COX-2 to modulate the eicosanoid synthesis pathway. By blocking the active site of these enzymes, the drug prevents the conversion of arachidonic acid into prostanoids, such as Prostaglandin E2 ( PGE2).

Modulation of Inflammatory Mediator Production

This mechanism centers on the inhibition of COX-2, the enzyme primarily responsible for the heightened production of pro-inflammatory prostaglandins at injury sites. The resulting suppression of PGE2 synthesis reduces the localized vascular changes and capillary permeability, which restricts fluid extravasation and edema formation at the tissue site.

Dampening Nociceptive Signals and Thermal Regulation

The reduction of peripheral PGE2 levels contributes to the desensitization of nociceptors (pain receptors), thereby raising the threshold for nociceptive signal transmission. Simultaneously, the drug’s action in the hypothalamus corrects the chemical imbalance that causes the elevation of the body's core temperature set point, thus leading to the restoration of thermal homeostasis.

Constraints on Constitutive Physiological Processes

The drug’s non-selective binding profile also involves inhibiting the constitutive COX-1 enzyme. This action necessarily modulates the production of essential, protective prostanoids that regulate vital homeostatic functions, including the maintenance of gastric mucosal integrity and the fine-tuning of renal blood flow.

Berifen, whose active component is Diclofenac, is available in multiple routes, including oral (tablets, capsules, powder), topical (gel, solution, patch), rectal, intravenous (IV), and intramuscular (IM) injection. The application of the medicine generally follows the principle of using the lowest effective dosage for the shortest duration consistent with treatment goals.

The oral dosing regimen for chronic conditions such as osteoarthritis typically ranges from 100 mg to 200 mg per day, administered in divided doses, or as a single once-daily dose for extended-release forms. For acute pain, the maximum daily dose is generally limited to 150 mg. Frequency patterns vary from once daily to multiple times daily, such as four times daily for the topical gel formulation.

Administration instructions are formulation-specific. Specific forms like the oral powder are mixed with 1 to 2 ounces of water and consumed on an empty stomach. Conversely, enteric-coated tablets may be taken with food. A key procedural constraint is that all modified-release tablets must be swallowed whole and cannot be crushed, split, or chewed. For older adults, the use of the lowest possible dose is a standard consideration. Standard practice for a missed dose involves taking the next dose at the regular time, rather than attempting to double the dose.

Research evidence / Overview of studies for Berifen (Diclofenac)

---

Evidence for Managing Chronic Joint Pain and Inflammation

The research landscape for diclofenac as a subject of research for conditions characterized by fluctuating or episodic manifestations like chronic joint pain, such as osteoarthritis (OA) or rheumatoid arthritis (RA), is primarily based on formal clinical research. Studies include multiple Randomized Controlled Trials (RCTs) and summaries compiled in Systematic Reviews and Meta-analyses. Research examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. These trials typically focused on adults over short to intermediate periods, generally less than three months.

Studies monitored how symptoms evolved in the observed populations, and findings described patterns where participants recorded changes in pain scores and reported changes in functional status. This evidence contributes to the broader evidence landscape by providing insight into short-term changes.

Evidence for Acute Pain and Soft Tissue Injuries

For conditions associated with acute or disruptive episodes, such as pain from sprains, strains, or post-surgical discomfort, the research examined diclofenac through tightly controlled, short-term, placebo-controlled RCTs. Research explored outcomes describing episodic or acute changes, focusing on the immediate response following administration. These studies were relevant in trials assessing short-term or episodic symptom patterns, primarily including general adult populations.

Studies monitored responses over defined time intervals, often focusing on the first few hours or days after treatment. Research highlights changes measured during the study period related to patterns in pain intensity and localized swelling. Studies explored whether participants in the research examined had a differing requirement for supplementary pain relief medication compared to control groups.

Long-term Studies and Follow-up Duration in Research

When discussing the evidence base, it is important to understand the typical follow-up periods in research. Most controlled trials assessing outcomes for pain and inflammation are designed to capture short-term and intermediate-term changes, typically lasting 6 to 12 weeks. This provides evidence on initial symptom patterns but cannot fully address the sustained nature of the effects over several years.

For understanding long-term use, researchers often turn to large observational studies and ongoing post-market surveillance. While these studies help show what has been observed so far in real-world scenarios, they differ structurally from the controlled setting of an RCT. As a result, long-term effects are not fully established with the same level of certainty as short-term symptomatic outcomes, and data are still emerging.

---

What Research Shows About Evidence Quality and Gaps

The overall evidence for diclofenac regarding outcomes related to physical discomfort is characterized by a high volume of controlled studies that explored short-term symptomatic outcomes. However, the evidence quality varies across studies when considering specific, specialized applications or long-term use.

Key research limitations include the follow-up durations were limited in most randomized trials. Comparative evidence is lacking across all possible combinations of other available treatments and drug formulations. Furthermore, the findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly. Studies contribute to the broader evidence landscape by highlighting that long-term effects are not fully established, and this continues to be an area of ongoing scientific monitoring.

Key Studies & References

1. Topical diclofenac and its role in pain and inflammation: an evidence-based review
2. Diclofenac: new contraindications and warnings (Drug Safety Update)

How to Store and Dispose of Berifen

Proper storage and disposal are essential to maintain drug stability and safety. Based on regulatory labeling for related diclofenac products, the intact medicine should be stored in the original carton to protect it from light, and maintained at a controlled room temperature between 2 C and 30 C (36 F and 86 F). Do not freeze the product.

Specific products, such as the lyophilized powder for injection, are for single use only. Once reconstituted, the solution must be used promptly, typically within 8 hours. Any partially used vials must be discarded.

To ensure child safety, keep the medicine and related packaging waste out of the reach of children and pets. All disposal should be performed in accordance with local/regional regulations.